Advances in borderline resectable pancreatic adenocarcinoma

Area of Science:

• Oncology
• Surgical Oncology
• Gastroenterology

Background:

• Pancreatic adenocarcinoma is a leading cause of cancer mortality.
• Borderline resectable pancreatic cancer (BRPC) is a distinct clinical entity.
• Multidisciplinary care is essential for optimal pancreatic cancer management.

Purpose of the Study:

• To describe the current therapeutic strategies for borderline resectable pancreatic cancer (BRPC).
• To highlight the importance of a collaborative, multimodal treatment approach in BRPC.

Main Methods:

• Review of current surgical techniques for BRPC.
• Analysis of locoregional therapies in BRPC management.
• Evaluation of systemic therapy options for BRPC.

Main Results:

• BRPC necessitates specialized, integrated treatment plans.
• Collaborative efforts among oncologists are crucial for patient outcomes.
• Current therapeutic landscape includes surgery, locoregional, and systemic treatments.

Conclusions:

• A multidisciplinary and multimodal approach is the standard of care for BRPC.
• Effective management of BRPC relies on the joint expertise of medical, surgical, and radiation oncologists.
• Ongoing research continues to refine treatment strategies for BRPC.